Navigation Links
Pharsight Invited to Present on Modeling and Simulation at ARCS Australia Scientific Congress
Date:5/27/2008

Dr. Helen Kastrissios Will Present on Communicating the Value of

Pharmacodynamic Modeling in Clinical Drug Development

MOUNTAIN VIEW, Calif., May 27 /PRNewswire-FirstCall/ -- Pharsight Corporation (Nasdaq: PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Helen Kastrissios, Ph.D., senior scientist, Pharsight Strategic Consulting Services, has been invited to present to clinical and regulatory professionals attending the Association of Regulatory and Clinical Scientists (ARCS) 17th Annual Congress. The Congress will be held at the Sydney Convention and Exhibition Centre in Sydney, Australia from May 28-30, 2008. Dr. Kastrissios will present on May 30, joining other leading experts from the pharmaceutical industry and academia in a session on clinical applications of pharmacodynamic modeling in drug development.

Dr. Kastrissios' presentation, entitled "Communicating the Value of Pharmacodynamic Modeling in Drug Development," will include several case studies describing how predictive drug-disease models have been used to support dose selection, compare the product profile of a new drug versus marketed competitors utilizing public-source literature data, and communicate model-based results to clinical project teams to support program decision- making. Presentation slides from Dr. Kastrissios' talk will be available at http://www.pharsight.com following the ARCS Congress.

"Model-based drug development has significant value for optimizing drug therapy and for improving the confidence of drug development decisions," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "Drug development teams can benefit from the quantitative application of drug-disease models to simulate expected clinical responses of new compounds, to support critical program strategies and enhance study design decisions. Pharsight is pleased to participate at the ARCS Congress, where we look forward to sharing our perspective with industry colleagues on the strategic use of modeling and simulation to improve drug development knowledge, productivity and decision- making."

Further information on the ARCS Congress can be found at http://www.arcs.com.au.

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Registered Trademarks and Trademarks

Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trademarks of their respective companies or organizations.


'/>"/>
SOURCE Pharsight Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Pharsight Invited to Present on Antiviral Modeling and Simulation at DIA Adherence Workshop
2. Pharsight Strengthens Senior Management Team
3. Pharsight Announces Fiscal Fourth Quarter 2008 and Year End Earnings Release Date and Conference Call
4. Pharsight Signs New Diabetes Meta-Database Customer
5. Pharsight to Present at eClinical Forum
6. Pharsight to Host Webinar on Hepatitis C Virus (HCV) and HIV Drug-Disease Modeling
7. FDA and Pharsight Continue to Collaborate Under CRADA
8. Pharsight to Present at DIA Cardiac Safety Conference on December 4, 2007
9. Pharsight Achieves $7.3 Million in Quarterly Revenue
10. Pharsight Expands Global Consulting Services Teams
11. Pharsight to Host European Software Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Young ... offers services to communities throughout the greater Pittsburgh metropolitan region, is joining forces ... provide adaptive bicycles for differently-abled children. , Variety the Children’s Charity is a ...
(Date:4/21/2017)... , ... April 21, 2017 , ... The adage “Show, ... House, the next project in the company’s esteemed VISION House demonstration project series. Manifesting ... exactly the amount of resources they need to live affordably and abundantly without unduly ...
(Date:4/21/2017)... ... April 21, 2017 , ... The ... of Record (AOR) for Theravent, Inc. , the makers of a revolutionary ... Foundation Consumer Healthcare, is now working to expand distribution in anticipation of a ...
(Date:4/21/2017)... ... 2017 , ... Crossover Symmetry , an evidence based ... lifestyle company that provides Human Performance Training and education to tactical athletes. Together ... military officers and others in service through the development and conditioning of overall ...
(Date:4/21/2017)... ... April 21, 2017 , ... Alive for Wellness is ... overcome their mental health struggles. The Alive team uses advanced behavioral sciences treatment ... in dealing with a mental health struggle is based on 10 modalities of ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
(Date:4/19/2017)... 2017 Global Prostate Cancer Therapeutics Market: ... prostate cancer therapeutics market analyzes the current and ... of prostate cancer, launch of promising emerging therapies, ... new drugs & therapeutic biological products, and high ... lesser side effects are some of the drivers ...
(Date:4/19/2017)...  Sorrento Therapeutics, Inc. (NASDAQ: SRNE ... new treatments for cancer and other unmet medical ... announced underwritten public offering of 23,625,084 shares of ... of $2.00 per share, before deducting underwriting discounts ... Sorrento.  The net proceeds to Sorrento from this ...
Breaking Medicine Technology: